The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
MEKTOVI (Pierre Fabre Australia Pty Ltd)
Product name
MEKTOVI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
198 working days (255)
Active ingredients
binimetinib
Registration type
NCE/NBE
Indication
MEKTOVI in combination with BRAFTOVI (encorafenib) is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by a validated test.